Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Summary

We describe here a protocol for isolating myeloid cells from mouse skin and draining lymph node following intradermal injection of Plasmodium sporozoites. Flow cytometry of collected cells provides a reliable assay to characterize the skin and draining lymph node inflammatory response to the parasite.

Abstract

Malaria infection begins when the sporozoite stage of Plasmodium is inoculated into the skin of a mammalian host through a mosquito bite. The highly motile parasite not only reaches the liver to invade hepatocytes and transform into erythrocyte-infective form. It also migrates into the skin and to the proximal lymph node draining the injection site, where it can be recognized and degraded by resident and/or recruited myeloid cells. Intravital imaging reported the early recruitment of brightly fluorescent Lys-GFP positive leukocytes in the skin and the interactions between sporozoites and CD11c⁺ cells in the draining lymph node. We present here an efficient procedure to recover, identify and enumerate the myeloid cell subsets that are recruited to the mouse skin and draining lymph node following intradermal injection of immunizing doses of sporozoites in a murine model. Phenotypic characterization using multi-parametric flow cytometry provides a reliable assay to assess early dynamic cellular changes during inflammatory response to Plasmodium infection.

Introduction

Malaria is one of the deadliest infectious diseases in the world, killing more than half a million people per year. Infection by Plasmodium, the causal agent of the disease, begins by a pre-erythrocytic (PE) phase. During this phase, sporozoites injected into the host skin by a female Anopheline mosquito reach the liver via the bloodstream and differentiate inside hepatocytes into the parasite forms that infect red blood cells and cause the symptoms of the disease.

The PE stages of Plasmodium represent a privileged target for anti-malaria vaccination. Indeed, live attenuated vaccines against these stages, such as radiation attenuated sporozoites (RAS), genetically arrested parasites (GAP) or chemoprophylaxis and sporozoites (CPS) have demonstrated their capacity to protect both rodent and human hosts^1-9. In the rodent model, most vaccination studies are conducted utilizing intravenous immunization, which is the gold standard in terms of protective efficacy. However, the description of a skin stage and the importance of the skin-associated draining lymph node (dLN) in eliciting protection has changed our perception of the PE phase and emphasized the importance of the intradermal route of injection. Intravital imaging of P. berghei sporozoites injected into the skin of rodents has shown that only ~25% of the inoculum reaches the liver via the bloodstream. The remaining ~75% distributes between the proximal dLN (~15%) and the skin (~50%)^10,11, where a small proportion can transform and remain alive for weeks inside skin cells^12,13. Moreover, subsequent studies described that the establishment of effective protective immunity after intradermal immunization mainly takes place in the skin-dLN, where parasite specific CD8⁺ T cells are activated, and only marginally in the spleen or liver-dLNs^14,15.

While most studies have concentrated on the characterization of the effector cells implicated in the establishment of protective immune response, much less is known about the fate of live attenuated parasites injected into the skin, especially their interactions with the innate immune system. In particular, characterization of antigen-presenting cells involved in parasite antigen uptake, processing and presentation to CD8⁺ T cells is of critical importance, knowing that PE antigen acquisition can occur both in the skin and dLN compartments. Previous intravital imaging studies described an early influx of brightly fluorescent Lys-GFP positive cells in the skin following an infectious mosquito bite¹⁶ while early interactions between sporozoites and dendritic cells were observed in the dLN^10,17. More recently, it has been reported that sporozoites inoculated in the skin by mosquitoes increases the motility of both dendritic and regulatory T cells in the skin of mice, while a decrease number of antigen presenting cells was observed in the dLN¹⁸.

We aimed to identify and quantify more precisely the leukocyte subsets recruited in the skin and corresponding dLN as well as those interacting with the parasite following intradermal injection of immunizing doses of RAS¹⁹. In this context, we isolated myeloid cells (CD45⁺CD11b⁺) from both tissues and characterized subpopulations of interest by multi=parametric flow cytometry. Consistent with the immune response described in the early stage of Leishmania major skin infection²⁰, the primary host response to sporozoite injection consists of a successive recruitment of polymorphonuclear neutrophils (CD45⁺CD11b⁺Ly6G⁺Ly6C^int) followed by inflammatory monocytes (CD45⁺CD11b⁺Ly6G^-Ly6C⁺) which are identified on the basis of differential expression of the Ly6G and Ly6C surface markers.

We describe here a protocol for isolating myeloid cells from the mouse skin and dLN following intradermal injection of immunizing doses of RAS extracted from infected mosquito salivary glands. Reproducible intradermal injections and tissue processing are critical steps to quantify phenotypic changes of infiltrating cell population within infected tissues. The approach detailed below provides a reliable assay to assess the skin and dLN inflammatory response to Plasmodium parasite and can be extended to various experimental systems.

Protocol

All procedures were approved by the committee of the Pasteur Institute and by the local Ethics Committee on Animal Experimentation (Ethical committee IDF-Paris 1, Paris, France; agreement number: 2012-0015) and performed in accordance with the applicable guidelines and regulations. 

1. Materials and Reagents

1. Use female Anopheles stephensi mosquitoes (Sda500 strain) that feed on infected mice 3-5 days after emergence and rear as described previously²¹.
2. Use parasites Plasmodium berghei ANKA clone expressing the Green Fluorescent Protein (GFP) gene under the control of the constitutive Heat Shock Protein 70 (HSP70) promoter. This yields bright fluorescence throughout the parasite life cycle²².
3. Use female C57BL/6JRj mice (7 week-old).
   NOTE: All the reagents used in the described protocol are listed in the Table of Materials/Equipment.

2. Radiation-attenuated Sporozoite Isolation from Mosquito Salivary Glands

1. Between 18-25 days after the infectious blood meal, collect and cold-anesthetize mosquitoes into a 15 ml tube on ice as described previously²¹. Carefully transfer them onto a Petri dish by inverting the tube. Maintain the insects on ice and expose the mosquitoes to a 12 krad dose of γ- or x-irradiation.
2. Isolate attenuated sporozoites from irradiated mosquito salivary glands as previously described²¹. Collect infected salivary glands in a small volume (around 15 μl) of 1x Dulbecco's phosphate-buffered saline (DPBS) on ice and gently crush them to release sporozoites.
   NOTE: The injection of a highly concentrated parasite suspension in a small volume being critical, it is therefore essential to harvest a sufficient number of salivary glands from a high number of preselected well-infected mosquitoes, as evidenced by their robust expression of green-fluorescence.
3. Filter the sporozoite suspension through a 35 µm cell strainer cap adapted to a low adhesion 1.5 ml microcentrifuge tube in order to eliminate clumps and mosquito debris.
4. Count the total number of isolated sporozoites as previously described²¹ and adjust the concentration of parasite suspension with cold 1x DPBS to obtain 83,000 sporozoites/μl. Store the parasites on ice while continuing the next steps.
5. Collect the equivalent number of salivary glands from uninfected mosquitoes that will be used as negative control and process the sample as described in steps 2.2 and 2.3. Dilute the sample as indicated above to obtain similar concentration of salivary gland extracts in the suspension.
   NOTE: Sporozoites can be stored on ice for a maximum of 2 hr. However, ideally they are injected within an hour after crushing the salivary glands.

3. Injection of Sporozoites into the Dermal Layer of the Ear

1. Anesthetize animals by intraperitoneal injection of ketamine (50 mg/kg)/xylazine (5 mg/kg) mixture. Wait 5-8 min for the mouse to be in a state of unconsciousness and apply ophthalmic ointment to the eyes to prevent corneal drying. Evaluate the depth of anaesthesia by performing a gentle toe pinch on both rear feet.
   NOTE: The dose of anaesthesia lasts for less than 20 min, so the next steps must be done quickly.
2. Stabilize the ear pinna of the mouse by fixing the ventral side with clear tape previously placed under a stereomicroscope (Figure 1A). Gently press the ear to avoid damage of the vasculature.
3. Load a 10 μl syringe/35 gauge bevelled needle with 0.6 µl of resuspended parasites¹⁰.
4. Deliver the sporozoite suspension in 4 injection sites (0.15 µl per site) by carefully inserting the needle on the dorsal side of the ear (Figure 1A), beneath the epidermis, with the bevel up, taking care to avoid any blood vessels. Allow the needle to remain in the dermis for few sec to prevent backflow of the injectant before removing it. Observe a characteristic papule at each injection site at the end of the procedure (Figure 1B and 1C).
5. After injection, carefully remove the ear from the tape.
6. Inject the contralateral ear with the same dose of parasites by following the steps 3.2-3.4.
7. Inject 2 additional mice with either 0.6 µl of 1x DPBS or 0.6 µl of 1x DPBS + salivary gland extract from uninfected mosquitoes in order to evaluate the inflammatory response mediated by the injection alone and the deposition of mosquito material in the dermis.
8.  Monitor mouse recovery from anaesthesia before placing it back into the cage.
   NOTE: The proper sporozoite deposition in the skin can be monitored by fluorescence microscopy (Figure 2A and 2B), the mouse being prepared as described previsously²³.

4. Skin and Draining Lymph Node Dissection 

1. Prepare standard medium (SM) as follows: Dulbecco's Modified Eagle Medium (DMEM) + 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) supplemented with 400 U/ml collagenase and 50 μg/ml deoxyribonuclease (DNase).
2. Prepare two 6 well flat-bottom tissue culture plates on ice with 4.5 ml SM + 70 μm cell strainer per well for dLN samples (Plate A) and 4.5 ml SM per well for skin samples (Plate B).
3. At the desired time point following sporozoite inoculation, deeply anesthetize the mouse by intraperitoneal injection of ketamine (125 mg/kg)/xylazine (12.5 mg/kg) mixture prior cervical dislocation. Make sure the mouse demonstrates signs of clinical death and start the dissection immediately.
   NOTE: The kinetics of myeloid cell recruitment can be examined at different times after injection (i.e. 2 hr, 4 hr and 24 hr as previously described¹⁴).
4. Disinfect the inoculated ear and the corresponding neck region with 70% ethanol to reduce the possibility of contamination.
5. Using sterile scissors and forceps, aseptically dissect the proximal auricular dLN without collecting the surrounding fat. Perform a first incision in the jugulo-carotidian sulcus and remove the hairs from the operating field. Stretch the incision with 2 forceps to expose the dLN that appears grayish compared to the surrounding tissue.
6. Pinch the connective tissues carefully on the top of the dLN with forceps to facilitate its removal. Extract the dLN by placing a forceps underneath the lymphoid tissue (Figure 3A and 3B). Place the dLN in a well containing 4.5 ml SM + 70 μm cell strainer (Plate A).
7. Harvest the entire inoculated ear using sterile sharp scissors and forceps (Figure 4A). Separate the dorsal and ventral aspects of the ear by pinching and spacing apart the cut ends with two forceps (Figure 4B-4E). Place them into a well containing 4.5 ml SM (Plate B) making sure both tissues are completely immersed in the medium.
   NOTE: In order to improve the reliability of the experiment and increase the number of cells of interest, pool 2 injected ears or 2 dLNs from the same mouse per sample.
8. Harvest and process in parallel the ears and dLNs of mice inoculated with either 1x DPBS or salivary gland extracts. Include 2 additional ear and lymph node samples harvested from a naive mouse for negative and single staining compensation controls.

5. Cell Isolation from Lymph Nodes

1. Incubate the lymph nodes (Plate A) at 37 °C + 5% CO₂ for 15 min under gentle agitation. Add 10 mM final Ethylenediaminetetraacetic acid (EDTA) per well to neutralize collagenase and DNase activities. Perform the next steps on ice.
2. Dissociate lymph nodes using the top end of a 5 ml syringe plunger. Press in circular motions against the strainer until all that remains is white connective tissues.
3. Rinse the cell strainer twice with 500 μl 1x DPBS + 2% Fetal bovine serum (FBS) + 2mM EDTA. Transfer entire volume of the well in a 15 ml tube.
4. Rinse the well twice with 500 μl 1x DPBS + 2% FBS + 2mM EDTA and transfer the volume into the 15 ml tube. Keep tubes on ice.

6. Cell Isolation from Skin of the Ear

1. Incubate the ear leaflets (Plate B) at 37 °C + 5% CO₂ for 1 hr under gentle agitation.
   NOTE: After 20 min of incubation, cut the ear leaflets with scissors into small pieces to facilitate tissue digestion and put the sample back in the incubator for the remaining 40 min. Single cells can be observed in the medium at the end of the incubation time.
2. Add 10 mM final EDTA per well to neutralize collagenase and DNase activities. Perform the next steps on ice.
3. Transfer the ear tissue fragments and the whole volume of medium in a new well containing a 70 μm cell strainer using a 1ml pipette. Cut 2 to 3 mm from the end of the tip to collect the ear tissue fragments more easily.
4. Dissociate ear tissue fragments using the top end of a 5 ml syringe plunger. Press in circular motions against the strainer until all that remains is white connective tissues.
5. Rinse the cell strainers twice with 500 μl 1x DPBS + 2% FBS + 2 mM EDTA.
6. Transfer the entire volume of the well into a 50 ml-tube through a 70 μm cell strainer.
7. Rinse the well with 500 μl 1x DPBS + 2% FBS + 2 mM EDTA and transfer the volume into the 50 ml tube. Keep the tube on ice.
   NOTE: The different steps to isolate total cells from the skin and dLN tissues are summarized in Figure 5.

7. Count and Viability of Collected Cells

1. Centrifuge the skin and dLN samples for 5 min at 450 x g at 4 °C and discard the supernatant. Gently resuspend the pellet with 300 μl 1x DPBS + 2% FBS + 2 mM EDTA.
2. Collect a small volume of each sample to count the total number of cells isolated from the skin and dLN using a hemocytometer. Add 0.04% trypan blue to determine the cell viability.

8. Blocking of Non Antigen-specific Binding

1. Add 10 µg/ml of unlabelled CD16/CD32 Fc-block antibody. Incubate 20 min at 4 °C (can go longer).
2. Add 2 ml of cold 1x DPBS + 2% FBS + 2 mM EDTA. Centrifuge the sample for 5 min at 450 x g at 4 °C and discard the supernatant. Gently resuspend the pellet with 300 μl 1x DPBS + 2% FBS + 2 mM EDTA and maintain the samples on ice.

9. Staining Skin and Lymph Node Myeloid Cells

1. Incubate previously blocked skin and dLN isolated cells with Live/Dead tracker (i.e. 4',6-diamidino-2-phenylindole or DAPI), anti-CD45 and anti-CD11b specific antibodies.
   NOTES: In order to enrich the myeloid cell subpopulations of interest, especially rare ones, CD45⁺ cells and lymphocytes can be respectively purified from the skin or depleted from the dLN by magnetic bead facilitating cell sorting. Since most of the cells isolated from the dLN are CD45⁺, the use of anti-CD45 is not mandatory. Other markers can be included to identify myeloid cell subpopulations of interest by positive or negative-gating strategy. In this protocol, the myeloid cells recruited in the dLN were enriched by excluding CD8α⁺ cells (the whole T cell compartment can be targeted by using anti-CD3 specific antibody).
2. Incubate 30 min at 4 °C in the dark. Add 500 μl 1x DPBS + 2% FBS + 2 mM EDTA, centrifuge the sample 5 min at 450 x g at 4 °C and discard the supernatant. Repeat the wash step twice.
3. Resuspend the samples with 300 μl 1x DPBS + 2% FBS + 2 mM EDTA. Transfer the entire volume in a FACS tube through a 35 µm cell strainer. Rinse the filter with 100 μl 1x DPBS + 2% FBS + 2 mM EDTA.
4. Run the stained cells in a flow cytometer. Gate live single cells (DAPI^-,FSC-W) to exclude dead cells and doublets. Plot CD45⁺CD11b⁺ events for the skin (Figure 6A) and (CD45⁺)CD8α^-CD11b⁺ events for the dLN (Figure 6B).

Results

We recently demonstrated that needle-syringe injection of immunizing doses of P. berghei sporozoites in the mouse skin induces a successive recruitment of polymorphonuclear neutrophils followed by inflammatory monocytes in the skin and dLN¹⁹. The Protocol Section described above details the procedure used to successfully isolate live myeloid cells from both tissues following multiple injections of large number of sporozoites in the ear dermis (Figures 1

Discussion

In the perspective of large-scale vaccination of humans using a whole sporozoite malaria vaccine, one of the main challenges to overcome is to develop optimized routes and methods of parasite administration to ensure successful immunization and protection^24,25. In humans, the evaluation of protective efficacy mediated by live attenuated parasites (LAP) has been performed following natural mosquito bites², as well as intradermal, subcutaneous^25,26 and IV immunizations²⁷. As repo...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Ketamine: Imalgene® 1,000	Merial	-	50 mg/kg: prior sporozoite injection 125 mg/kg: prior sacrifice
Xylazine: Rompun® 2%	Bayer	-	5 mg/kg: prior sporozoite injection 12.5 mg/kg: prior sacrifice
NanoFil syringe + 35 gauge needle	World Precision Instruments	-	-
Omnican® 50 Insulin syringe 0.5 ml/50 I.U.	B. Braun Medical	9151125	-
MultiwellTM 6 well tissue culture plate – Flat Bottom	BD Falcon	353046	-
70 µm cell strainer	BD Falcon	352350	-
2 ml syringe	Terumo	SS-02S	-
BLUE MAXTM 15 ml Polypropylene conical tube	BD Falcon	352097	-
BLUE MAXTM 50 ml Polypropylene conical tube	BD Falcon	352098	-
5 ml Polystyrene Round-Bottom Tube with 35 µm Cell-Strainer Cap	BD Falcon	352235	-
DPBS 1x CaCl2- and MgCl2--free	Life Technologies	14190-094	-
DMEM 1x + GlutaMAXTM	Life Technologies	31966-021	-
Collagenase from Clostridium histolyticum, Type IV 0.5-5.0 FALGPA units/mg solid	Sigma-Aldrich	C5138	400 U/ml
Deoxyribonuclease I from bovine pancreas, type IV	Sigma-Aldrich	D5025	50 µg/ml
EDTA disodium salt	Sigma-Aldrich	E-5134	10 mM or 2.5 mM
FBS	Biowest	S1810-500	-
HEPES buffer solution (1M)	Gibco	15630-056	25 mM
Trypan blue Stain (0,4%)	Life Technologies	15250-061	Dilution 1:10
Anti-mouse CD16/CD32 (2.4G2 clone)	BD Biosciences	553142	10 µg/ml final (1:50)
DAPI FluoroPureTM grade	Life Technologies	D21490	1 µg/ml final
Anti-mouse CD45 (30-F11 clone)	BD Biosciences	559864	Dilution 1:200
Anti-mouse CD11b (M1/70 clone)	BD Biosciences	557657	Dilution 1:400
Anti-mouse CD8α (5H10 clone)	Life Technologies	MCD0830	Dilution 1:100
Female C57BL/6JRj mice (7-week-old)	Janvier Laboratories	-	-